Skip to main content
Click here to get access to our Free Course on Momentum Investing Strategy

NSE · JAGSNPHARM

JAGSON PHAR

HealthcarePharmaceuticals & Biotechnology₹1379 cr market cap
₹210.39 ▲ +1.02% today As of 19 Nov 2026
52-week low ₹161.0752-week high ₹243.97

-14.6% from the 52-week high · +29.3% above the low

Jagsonpal Pharmaceuticals Ltd. is a pharmaceutical company, which engages in the development and manufacture of intermediate drugs and pharmaceutical formulations. The company is headquartered in New Delhi, Delhi and currently employs 940 full-time employees. The firm is primarily engaged in the manufacturing and trading of pharmaceutical products and active pharmaceutical ingredients (APIs). Its formulation products include Divatrone, Maintane 500 injection, Maintane 250 injection, Maintane Tablet, Indocap capsules, Metadec 50 injection, Metadec 25 injection, EndoReg Tablet, LycoRed softgels, LycoRed syrup, Doxypal DR-L Capsule, Yuliprist Tablet, COLLA-2 Tablet, Cystelia M, and DeeReg Tablet, among others. Its OTC products include Ringcuter Cream, Skin Lumia Soap-Antibacterial, and Skin Lumia Soap-Neem Tulsi. Its Naari products include Endoreg, Yuliprist, Verena, Kyrah, Krampoff, Endonorm EV2, Divagest SR 300, Divagest SR 200, Cystelia 35, Fibristone 25, and Cystelia-M. Its other products include Lycored Softgels, Lycored Syrup, JP Tone Syrup, and Doxypal DR-L. The Company’s therapy areas include gynecology, orthopedics, and others.

The short version. Promoter holding was 68.81% in Sep 2026, up 1.00 points over 8 quarters.

1 · The price

How has the stock traded?

JAGSON PHAR trades 14.6% below its 52-week high and 29.3% above its 52-week low.

Change over period: —

1M-4.3%
3M-9.6%
6M+4.5%
1Y-1.4%

2 · The business

Is it growing?

Reported results · ₹ crore

Revenue and profit

Show the numbers

Quarterly

Sep 2026
Revenue96
Net profit12
Net margin %12.8
EPS (₹)1.86

4 · The owners

Who holds it, and are they adding?

Promoter holding68.81%

Up 1.0 pts over 8 quarters.

Foreign institutions2.14%

Up 0.04 pts over 8 quarters.

Domestic institutions1.65%

Up 1.65 pts over 8 quarters.

Mutual fund schemes2

+0 versus the previous month.

Shareholding pattern (%)

Quarter by quarter

Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026Change
Promoter67.8167.7867.6567.5467.3967.8969.0568.81+1.0
FII2.12.12.182.122.122.442.32.14+0.04
DII000.050.090.150.220.621.65+1.65
Public30.0830.1130.1230.2530.3429.4528.0327.4-2.68

Mutual fund holdings · Oct 2026

2 schemes hold this stock

2 the month before.

  • Motilal Oswal BSE Healthcare ETF0.02% of NAV
  • Bandhan BSE Healthcare Index Fund0.02% of NAV

See what mutual funds are buying

5 · The model view

What does our factor model say?

Factor scores, model flags and screen results for JAGSON PHAR are part of the Wright portfolio review.

Run your free portfolio review

Watchouts

What to review

Model flags are shown inside the portfolio review, alongside your other holdings.

Model ratingLocked
Factor betaLocked
VolatilityLocked

Quick answers

Common questions about JAGSON PHAR

What is the JAGSON PHAR share price?

JAGSON PHAR (JAGSNPHARM) last closed at ₹210.39, up 1.02% on the day. Its 52-week range is ₹161.07 to ₹243.97.

What is the market cap of JAGSON PHAR ?

JAGSON PHAR has a market capitalisation of about ₹1,379 crore. Its price-to-earnings ratio is 31.2.

How are JAGSON PHAR 's latest results?

Promoter holding was 68.81% in Sep 2026, up 1.00 points over 8 quarters.

Who owns JAGSON PHAR ?

As of Sep 2026, shareholding was: Promoter 68.81%, FII 2.14%, DII 1.65%, Public 27.4%.

How many mutual funds hold JAGSON PHAR ?

2 mutual fund schemes held JAGSON PHAR in October 2026. That compares with 2 the month before.

Corporate actions

Recent dividends, bonuses and splits

  • 12 Sep 2025 · Final Dividend - Rs. 2.5
  • 08 Jan 2025 · Stock Split From Rs.5/- to Rs.2/-
  • 06 Sep 2024 · Final Dividend - Rs. 5
  • 21 Aug 2023 · Dividend - Rs. 5
  • 29 Oct 2021 · Interim Dividend - Rs. 4
  • 22 Sep 2021 · Dividend - Rs. 1

Financials are as reported by the company (consolidated), in ₹ crore. Source: FinEdge exchange filings feed. Figures can differ from other sites because of one-off items and restatements. Callouts above are arithmetic on reported data, not recommendations.

Research data on this page is provided under Wright Research's SEBI Research Analyst registration. The Terms & Conditions of our Research Analyst services apply.